Effects of ACE Inhibitors or ↓-Blockers in Patients Treated with the Fixed-Dose Combination of Isosorbide Dinitrate/Hydralazine in the African-American Heart Failure Trial

[1]  Anne L. Taylor,et al.  Early and Sustained Benefit on Event-Free Survival and Heart Failure Hospitalization From Fixed-Dose Combination of Isosorbide Dinitrate/Hydralazine: Consistency Across Subgroups in the African-American Heart Failure Trial , 2007, Circulation.

[2]  K. Hryniewicz,et al.  Comparison of metabolic vasodilation in response to exercise and ischemia and endothelium-dependent flow-mediated dilation in African-American versus non-African-American patients with chronic heart failure. , 2006, The American journal of cardiology.

[3]  F. O'Valle,et al.  Effects of angiotensin-converting-enzyme inhibitors in combination with diuretics on blood pressure and renal injury in nitric oxide-deficiency-induced hypertension in rats. , 2006, Clinical science.

[4]  D. Angus,et al.  Cost-Effectiveness of Fixed-Dose Combination of Isosorbide Dinitrate and Hydralazine Therapy for Blacks With Heart Failure , 2005, Circulation.

[5]  J. Ghali.  Beta-blockers in selected heart failure populations , 2005, Current heart failure reports.

[6]  Ralph D'Agostino,et al.  Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. , 2004, The New England journal of medicine.

[7]  J. Kleijnen,et al.  Systematic Review: Antihypertensive Drug Therapy in Black Patients , 2004, Annals of Internal Medicine.

[8]  Rongling Li,et al.  Relation of endothelial nitric oxide synthase gene to plasma nitric oxide level, endothelial function, and blood pressure in African Americans. , 2004, American journal of hypertension.

[9]  A. Sehgal.  Overlap Between Whites and Blacks in Response to Antihypertensive Drugs , 2004, Hypertension.

[10]  J. Laragh,et al.  Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients. , 2004, American journal of hypertension.

[11]  S. Gottlieb,et al.  Metoprolol CR/XL in black patients with heart failure (from the Metoprolol CR/XL randomized intervention trial in chronic heart failure). , 2003, The American journal of cardiology.

[12]  J. Ghali.  Race, ethnicity, and heart failure. , 2002, Journal of cardiac failure.

[13]  J. Panza,et al.  Reduced endothelium-dependent and -independent dilation of conductance arteries in African Americans. , 2002, Journal of the American College of Cardiology.

[14]  J. Loscalzo,et al.  Effects of Black Race on Forearm Resistance Vessel Function , 2002, Hypertension.

[15]  M. Drazner,et al.  Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. , 2002, Journal of the American College of Cardiology.

[16]  V. Smith,et al.  The presence of African American race predicts improvement in coronary endothelial function after supplementary L-arginine. , 2002, Journal of the American College of Cardiology.

[17]  Xiao-Ping Yang,et al.  Effect of ACE Inhibitors and Angiotensin II Type 1 Receptor Antagonists on Endothelial NO Synthase Knockout Mice With Heart Failure , 2002, Hypertension.

[18]  M. Domanski,et al.  Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. , 2001, The New England journal of medicine.

[19]  C. Yancy,et al.  Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. , 2001, The New England journal of medicine.

[20]  C. Lang,et al.  Increased Vascular Adrenergic Vasoconstriction and Decreased Vasodilation in Blacks: Additive Mechanisms Leading to Enhanced Vascular Reactivity , 2000, Hypertension.

[21]  J. Cohn,et al.  Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. , 1999, Journal of cardiac failure.

[22]  B. Gersh,et al.  Racial differences in the outcome of left ventricular dysfunction. , 1999, The New England journal of medicine.

[23]  R. Cannon,et al.  Attenuation of cyclic nucleotide-mediated smooth muscle relaxation in blacks as a cause of racial differences in vasodilator function. , 1999, Circulation.

[24]  R. Cannon,et al.  Racial differences in nitric oxide-mediated vasodilator response to mental stress in the forearm circulation. , 1998, Hypertension.

[25]  S. Fujii,et al.  In vivo three-dimensional EPR imaging of nitric oxide production from isosorbide dinitrate in mice. , 1998, American journal of physiology. Gastrointestinal and liver physiology.

[26]  C. Lang,et al.  Vasodilation in black Americans: Attenuated nitric oxide‐mediated responses , 1997, Clinical pharmacology and therapeutics.

[27]  S. Rajagopalan,et al.  Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. , 1996, The Journal of clinical investigation.

[28]  A. J. Walker,et al.  Racial differences in maximal vasodilatory capacity of forearm resistance vessels in normotensive young adults. , 1992, American journal of hypertension.